GR3025655T3 - Determination of peptide motifs on mhc molecules. - Google Patents

Determination of peptide motifs on mhc molecules.

Info

Publication number
GR3025655T3
GR3025655T3 GR970403308T GR970403308T GR3025655T3 GR 3025655 T3 GR3025655 T3 GR 3025655T3 GR 970403308 T GR970403308 T GR 970403308T GR 970403308 T GR970403308 T GR 970403308T GR 3025655 T3 GR3025655 T3 GR 3025655T3
Authority
GR
Greece
Prior art keywords
peptide motifs
determination
mhc molecules
disclosed
mhc
Prior art date
Application number
GR970403308T
Other languages
English (en)
Inventor
Olaf Roetzschke
Kirsten Falk
Stefan Stevanovic
Guenther Jung
Hans-Georg Rammensee
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of GR3025655T3 publication Critical patent/GR3025655T3/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
GR970403308T 1992-11-13 1997-12-10 Determination of peptide motifs on mhc molecules. GR3025655T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4238416A DE4238416A1 (de) 1992-11-13 1992-11-13 Bestimmung von Peptidmotiven auf MHC-Molekülen
PCT/EP1993/003175 WO1994011738A1 (de) 1992-11-13 1993-11-12 Bestimmung von peptidmotiven auf mhc-molekülen

Publications (1)

Publication Number Publication Date
GR3025655T3 true GR3025655T3 (en) 1998-03-31

Family

ID=6472850

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970403308T GR3025655T3 (en) 1992-11-13 1997-12-10 Determination of peptide motifs on mhc molecules.

Country Status (11)

Country Link
EP (1) EP0669001B1 (el)
JP (1) JPH07509319A (el)
KR (1) KR100194117B1 (el)
AT (1) ATE158082T1 (el)
AU (1) AU673212B2 (el)
CA (1) CA2147863C (el)
DE (2) DE4238416A1 (el)
DK (1) DK0669001T3 (el)
ES (1) ES2109658T3 (el)
GR (1) GR3025655T3 (el)
WO (1) WO1994011738A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US5610013A (en) * 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
WO1998020902A1 (fr) * 1996-11-13 1998-05-22 Meiji Milk Products Co., Ltd. Agent immunotherapeutique peptidique
AU7298398A (en) * 1996-11-19 1998-06-10 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
ATE445643T1 (de) 1999-11-18 2009-10-15 Pharmexa Inc Heteroklitische analoga von klasse-i epitopen
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
KR100863632B1 (ko) 2000-03-31 2008-10-15 퍼듀 리서치 파운데이션 리간드-면역원 접합체를 사용한 치료 방법
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
EP1781313A4 (en) 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US20160310583A1 (en) * 2013-10-03 2016-10-27 Sumitomo Dainippon Pharma Co., Ltd. Tumor antigen peptide
WO2020037046A1 (en) * 2018-08-14 2020-02-20 Board Of Regents, The University Of Texas System Single molecule sequencing peptides bound to the major histocompatibility complex

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU619458B2 (en) * 1987-01-30 1992-01-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte inhibition by hla peptides
DE4143467C2 (de) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung

Also Published As

Publication number Publication date
ATE158082T1 (de) 1997-09-15
KR950704688A (ko) 1995-11-20
KR100194117B1 (ko) 1999-06-15
CA2147863A1 (en) 1994-05-26
ES2109658T3 (es) 1998-01-16
JPH07509319A (ja) 1995-10-12
DE4238416A1 (de) 1994-05-19
AU5465694A (en) 1994-06-08
EP0669001A1 (de) 1995-08-30
CA2147863C (en) 2002-12-24
EP0669001B1 (de) 1997-09-10
DE59307354D1 (de) 1997-10-16
AU673212B2 (en) 1996-10-31
DK0669001T3 (da) 1998-05-04
WO1994011738A1 (de) 1994-05-26

Similar Documents

Publication Publication Date Title
GR3025655T3 (en) Determination of peptide motifs on mhc molecules.
CA2103148A1 (en) Determination of motifs of peptides on mhc molecules
NL300140I2 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
AU4725796A (en) Preparation and use of a specific gaba-A alpha 5 receptor ligand for treatment of Alzheimer's disease
FI991477A (fi) Menetelmä tolterodiinin valmistamiseksi
GEP20033094B (en) Steroid Sulphatase Inhibitors
GB9126725D0 (en) Process
AU6393686A (en) Process for preparing halogen magnesium alanate and use thereof
PT85121A (en) Process for the preparation of new androst-4-ene-3,17-diones
FI891473A (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-aryyli-4-piperidiinikarbinolien valmistamiseksi
IL65597A (en) Preparation of 1alpha,24,25-trihydroxy-and 24,25-dihydroxy-cholesterol and certain novel intermediates used therein
DE69007637D1 (de) Verfahren zur Herstellung von 1,1,3,4,4,6-Hexamethyl-1,2,3,4-tetrahydronaphthalin.
UA35556C2 (uk) Спосіб одержання гідрокортизону та проміжні сполуки в синтезі гідрокортизону
TW326033B (en) Cyanobenzenesulfenyl halide and process for preparation of 3-substituted benzisothiazole using the same
NO903338D0 (no) Fremgangsmaate for mikrobiologisk fremstilling av l-carnitin.
AU1966888A (en) Process for stabilizing mixtures based on halogenated polymers
GR1001203B (el) Μεθοδος παρασκευης της ενωσεως 24r-σκυμνολη.
ATE73136T1 (de) Verfahren zur herstellung von 6alpha, 9alphadifluor-11beta, 17alpha-dihydroxy-16alpha-methyl4-pregnen-3,20-dion und dessen derivate.
HU913573D0 (en) Complexes containing s(+)alkaneacids and alpha-hydroxy-alkaneacids
FR2703994B1 (fr) Procédé de préparation de beta-lactames.
JO1493B1 (en) Pharmaceutical combination for treating high blood pressure
AU1568995A (en) Analogs of thymosin alpha1
ES2019047A6 (es) Un procedimiento para la preparacion de benzamidas.
RO102204A2 (ro) Instalatie pentru sinteza poliizocianatilor
ATE84520T1 (de) (+-)- oder (+)-1-(2-n-substituiertes aminoaethyl)1-methyl-7-methoxy-1,2,3,4-tetrahydronaphthalen und verfahren zu dessen herstellung.